These results demonstrate that the aCD20@ExoCTX/siPDK4 exosome nanoparticle complex effectively inhibits PDK4 and, through dephosphorylation of nuclear HDAC8, upregulates CD20 expression, thereby reversing the molecular mechanism of rituximab resistance in DLBCL. Here, HDAC8 is linked to diffuse large B-cell lymphoma.